Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: Results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study

Archives of Internal Medicine

Volumn 166, Issue 6, 2006, Pages 659-666

  Ferrari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; PERINDOPRIL; PLACEBO;

ACUTE HEART INFARCTION; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRESSLER SYNDROME; DRUG FATALITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; TREATMENT WITHDRAWAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; PERINDOPRIL; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 33645469422     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.6.659     Document Type: Article

References (29)

1. Nicolosi GL, Latini R, Marino P, et al; Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Eur Heart J. 1996;17:1646-1656.
2. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68-75.
3. Greenberg B, Quinones MA, Koilpillai C, et al; SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation. 1995;91:2573-2581.
4. Borghi C,, Marino P, Zardini P, et al; FAMIS Working Party. Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS). Am J Hypertens. 1997;10:247S-254S.
5. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411-3419.
6. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J; CONSENSUS II Multi-Echo Study Group. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol. 1993;72:1004-1009.
7. Flather MD, Yusuf S, Kober L, et al; ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
8. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
9. Diller PM, Smucker DR, David B, Graham RJ. Congestive heart failure due to diastolic or systolic dysfunction: frequency and patient characteristics in an ambulatory setting. Arch Fam Med. 1999;8:414-420.
10. Holmes DR Jr, White HD, Pieper HKS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol. 1999;33:412-419.
11. Latini R, Nicolosi G, Maggioni AP, et al; GISSI-3 Investigators. The beneficial effect of lisinopril on left ventricular remodelling after a first myocardial infarction is modulated by age: the GISSI-3 Echo database [abstract]. J Am Coll Cardiol. 1996;27(2)(suppl 1):281A.
12. PREAMI Investigators. PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: study rationale and design. Cardiovasc Drugs Ther. 2000;14:671-679.
13. GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarction. Am J Cardiol. 1992;70:62C-69C.
14. Schiller NB, Shah PM, Crawford M, et al; American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by twodimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-367.
15. Giannuzzi P, Temporelli PL, Bosimini E, et al. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo substudy. Am Heart J. 2001;141:131-138.
16. Bosimini E, Giannuzzi P, Temporelli PL, et al. Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo substudy. J Am Coll Cardiol. 2000;35:127-135.
17. Donner A, Eliasziw M. Sample size requirements for reliability studies. Stat Med. 1987;6:441-448.
18. Moyé LA. Analysis of clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Stat Med. 1992;11:1705-1717.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977;35:1-39.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of diseases. J Natl Cancer Inst. 1959;22:719-748.
21. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255-259.
22. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;337:872-876.
23. Ambrosioni E, Borghi C, Magnani B. SMILE Pilot Study Working Party. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. Am J Cardiol. 1991;68:101D-110D.
24. European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet. 2003;362:782-788.
25. Scientific Committee of the PERTINENT Sub-Study. PERTINENT - Perindopril-Thrombosis, Inflammation, Endothelial Dysfunction and Neurohormonal Activation Trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther. 2003;17:83-91.
26. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
27. Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol. 2005;38:47-62.
28. Khattar RS. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure. Minerva Cardioangiol. 2003;51:143-154.
29. Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:e82-e292.